Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 15

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 15
---
: STAAR Quarterly Report on Form 10 - Q for the period ended June 27, 2025 at 23. 4. Consensus revenue per FactSet, as of August 4, 2025. 5. Source: STAAR Q1 2025 Earnings Call, May 7, 2025. 65% 66% 74% 75% - 80% 4Q24 1Q25 2Q25 Projected After Switzerland Manufacturing Ramp² FY 2020 - 2024 Average: ~77% 1 B Gross Margin 1

Broadwood Partners, L.P. 22 The Company’s second quarter 2025 financial results exceeded analyst expectations Source: FactSet and STAAR Quarterly Report on Form 10 - Q for the period ended June 27, 2025. $40.9 $44.3 Consensus Actual 64% 74% Consensus Actual ($24.2) ($14.9) Consensus Actual The Company’s Recent Financial Results Demonstrated Improvement (Continued) 1 B 2Q25 Net Sales ($M) 2Q25 Adjusted EBITDA ($M) 2Q25 Gross Margin

Broadwood Partners, L.P. STAAR’s Recent Actions Have Strengthened the Company 23 The Company is in a much stronger position than it was a few months ago Potential Implications What STAAR Said Date Announced Milestone The appointment of a new CEO was the first step in an “organizational reset” intended to transform the Company in response to dynamic market conditions; we believe the benefits of this leadership change have yet to be realized “I am excited to join STAAR as CEO at this critical time… We have a best - in - class product, a strong network of surgeons, and a clear path to continued market share gains in a market that we expect to grow substantially over time… The building blocks for STAAR’s success are in place , and I will be looking at opportunities for improvement, optimization, and efficiency.” 1 February 26, 2025 CEO Transition STAAR took steps to right - size the organization and reduce expenses, while also continuing to support R&D productivity, which we believe will help accelerate the Company’s path to profitability when the demand environment normalizes “I am confident that we have the right leadership team in place to fulfill our promise to patients, surgeons, and shareholders. Our primary objective continues to be long term revenue growth, and this commitment is